| SCHEDULE OF UNAUDITED PRO FORMA FINANCIAL INFORMATION |
SCHEDULE OF UNAUDITED PRO
FORMA FINANCIAL INFORMATION
| | |
| | | |
| | | |
| |
| | |
| | |
September
30, 2024 | |
| | |
(Unaudited) | |
| | |
Consolidated
Balance Sheet | | |
Proforma
Adjustments | | |
Notes | |
Proforma
Balance Sheet | |
| Cash | |
$ | 74,514 | | |
$ | 2,087,102 | | |
(a) | |
$ | 2,161,616 | |
| Current assets | |
| 371,593 | | |
| - | | |
| |
| 371,593 | |
| Total current
assets | |
| 446,107 | | |
| 2,087,102 | | |
| |
| 2,533,209 | |
| | |
| | | |
| | | |
| |
| | |
| Non-current
assets: | |
| 413,666 | | |
| - | | |
| |
| 413,666 | |
| Total
Assets | |
$ | 859,773 | | |
$ | 2,087,102 | | |
| |
$ | 2,946,875 | |
| | |
| | | |
| | | |
| |
| | |
| Current liabilities | |
$ | 3,356,493 | | |
$ | - | | |
| |
$ | 3,356,493 | |
| Non-current
liabilities | |
| 26,277 | | |
| - | | |
| |
| 26,277 | |
| Total
Liabilities | |
| 3,382,770 | | |
| - | | |
| |
| 3,382,770 | |
| | |
| | | |
| | | |
| |
| | |
| Ordinary shares (US$1 par value; 50,000 shares; authorized
13,727 shares issued) | |
| 13,727 | | |
| 892 | | |
(a) | |
| 14,619 | |
| Additional
paid-in capital | |
| 11,074,192 | | |
| 2,086,210 | | |
(a) | |
| 13,160,402 | |
| Subscription
receivables | |
| (2,939,179 | ) | |
| | | |
| |
| (2,939,179 | ) |
| Accumulated
other comprehensive loss | |
| (220,253 | ) | |
| | | |
| |
| (220,253 | ) |
| Accumulated
deficit | |
| (10,451,484 | ) | |
| | | |
| |
| (10,451,484 | ) |
| Total shareholders’
deficit | |
| (2,522,997 | ) | |
| 2,087,102 | | |
| |
| (435,895 | ) |
| Total
Liabilities and Shareholders’ deficit | |
$ | 859,773 | | |
$ | 2,087,102 | | |
| |
$ | 2,946,875 | |
Notes
to Proforma Consolidated Balance Sheet
| |
(a) |
Additional 892 were
shares issued for $2,087,102. |
MAIUS
PHARMACEUTICAL CO., LTD.
PROFORMA
CONSOLIDATED STATEMENTS OF OPERATIONS
| | |
| | | |
| | | |
| | |
| | |
Year Ended September 30, 2024 | |
| | |
As Reported | | |
Pro Forma Adjustment | | |
Pro Forma | |
| Net Loss(b) | |
$ | (629,176 | ) | |
$ | - | | |
$ | (629,176 | ) |
| Net loss per share attributable to ordinary shareholders basic and diluted | |
| (45.83 | ) | |
| — | | |
| (43.04 | ) |
| Weighted average number of
ordinary shares used in computing net loss per share basic and diluted(a) | |
| 13,727 | | |
| 892 | | |
| 14,619 | |
Notes
to Proforma Consolidated Statements of Operations
| |
(a) |
Additional 892 were
shares issued for $2,087,102. |
| |
(b) |
There are no effects
on total revenue and total net income. |
|